{{Rsnum
|rsid=2388449
|Gene=LOC729506
|Chromosome=5
|position=8444092
|Orientation=minus
|GMAF=0.3131
|Gene_s=SNORD19B
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(C;C)
|geno2=(C;T)
|geno3=(T;T)
}}{{ population diversity
| geno1=(C;C)
| geno2=(C;T)
| geno3=(T;T)
| CEU | 46.9 | 42.5 | 10.6
| HCB | 87.6 | 12.4 | 0.0
| JPT | 92.0 | 8.0 | 0.0
| YRI | 8.2 | 42.2 | 49.7
| ASW | 12.3 | 56.1 | 31.6
| CHB | 87.6 | 12.4 | 0.0
| CHD | 91.7 | 7.3 | 0.9
| GIH | 39.6 | 44.6 | 15.8
| LWK | 10.0 | 43.6 | 46.4
| MEX | 53.4 | 41.4 | 5.2
| MKK | 21.2 | 50.0 | 28.8
| TSI | 55.9 | 31.4 | 12.7
| HapMapRevision=28
}}{{PharmGKB
|RSID=rs2388449
|Name_s=
|Gene_s=-
|Feature=
|Evidence=PubMed ID:17537913
|Annotation=Risk or phenotype-associated allele: not stated Phenotype: Using a Quantitative Transmission Disequilibrium Test (QTDT), this variant was significantly associated with etoposide toxicity based upon IC50 values in cell lines from 30 parent-child trios. Study size: 176. Study population/ethnicity: 87 European descent Caucasians and 89 Yorubans. Significance metric(s): p = 0.00007. Type of association: FA; GN.
|Drugs=etoposide
|Drug Classes=
|Diseases=Drug Toxicity
|Curation Level=Curated
|PharmGKB Accession ID=PA165109437
}}

{{GET Evidence
|impact=pharmacogenetic
|qualified_impact=Insufficiently evaluated pharmacogenetic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs2388449
|overall_frequency_n=75
|overall_frequency_d=120
|overall_frequency=0.625
|n_genomes=39
|n_genomes_annotated=0
|n_haplomes=63
|n_articles=1
|n_articles_annotated=0
|in_pharmgkb=Y
|autoscore=1
|webscore=N
}}

{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | Affy GenomeWide 6}}